October 7, 2026 · Patent expires December 18, 2026

Ofev (Nintedanib): The 2026-2030 Generic Opportunity Window

Boehringer Ingelheim's multi-kinase inhibitor Ofev (nintedanib) generated EUR 3.9 billion ($4.2 billion USD) worldwide in 2024 for idiopathic pulmonary fibrosis and interstitial lung diseases. Core substance patent US 6,762,180 expires in June 2026 (extended to December 18, 2026 via pediatric exclusivity), opening a vital generic transition window through 2030 for Paragraph IV challengers including Cipla, Sun Pharma, Glenmark, and Natco Pharma.

What we do

We track expirations like this continuously

This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.